Meet the team
Medication Safety Officer (MSO) – Cardiff and Vale UHB Hi, I’ve been asked to share with you my experience in the role of Medication Safety Officer (MSO) – a part of my job I...
Author: Gail
Coronavirus (COVID-19) – Therapeutic advice via AWTTC.org
To aid in the appropriate use of medicines during the current Coronavirus (COVID-19) pandemic, AWTTC have provided therapeutic advice for information on the AWTTC.org website.
New e-Advice service for Primary Care
Did you know that The Welsh Medicines Information Centre now offer an e-Advice service? This service can be accessed using the current e-Advice platform produced and provided by Cardiff and Vale University Health Board:...
Updated Q&A – What is the most suitable treatment for acne in a patient with acute porphyria?
There is an update to the Porphyria Q&A for What is the most suitable treatment for acne in a patient with acute porphyria?
Updated Q&A – Considerations when addressing questions about potential for adverse effects and drug interactions with homeopathic remedies
There is an update to the Complementary medicine Q&A for ‘Considerations when addressing questions about potential for adverse effects and drug interactions with homeopathic remedies‘.
Updated Q&A – What is the risk of gastrointestinal bleeding associated with selective serotonin reuptake inhibitors (SSRIs)?
There is an update to the UKMi Medicines Q&A for ‘What is the risk of gastrointestinal bleeding associated with selective serotonin reuptake inhibitors (SSRIs)?‘
Updated Q&A – What advice should be given to patients with porphyria who intend to travel?
There is an update to the Porphyria Q&A for ‘What advice should be given to patients with porphyria who intend to travel?‘
How should crusted and other forms of difficult-to-treat scabies be managed?
This UKMi Q&A covers the management of crusted scabies and of classical scabies that is difficult to treat.
Shared care protocol CV42 methylphenidate for attention deficit hyperactivity disorder (ADHD), hyperkinetic disorder (HKD)
CV42 methylphenidate for attention deficit hyperactivity disorder (ADHD), hyperkinetic disorder (HKD). Access to Shared care supporting documents and list of additional Shared Care Protocols
Shared care protocol CV46 atomoxetine for attention deficit hyperactivity disorder (ADHD), hyperkinetic disorder (HKD) in children 6 years and older, adolescents and adults
CV46 atomoxetine for attention deficit hyperactivity disorder (ADHD), hyperkinetic disorder (HKD) in children 6 years and older, adolescents and adults. Access to Shared care supporting documents and list of additional Shared Care Protocols
